Ziqin Wang | Toxicology and Pharmaceutical Science | Innovative Research Award

Innovative Research Award

Ziqin Wang
Beijing Chaoyang Kaiwen Academy

Researcher Profile
Affiliation Beijing Chaoyang Kaiwen Academy
Country China
Subject Area Toxicology and Pharmaceutical Science
Event International Invention Awards
ORCID 0009-0004-2036-3316

Ziqin Wang is associated with Beijing Chaoyang Kaiwen Academy in China, with toxicology and pharmaceutical science identified as the relevant subject areas in the supplied profile. These disciplines investigate the biological effects of chemical substances, pharmaceutical safety, therapeutic development, and evidence-based approaches to evaluating medicines.methodological quality, and research relevance. Specific publications, research achievements, and bibliometric indicators require independent verification before attribution. Established toxicological assessment principles and pharmaceutical research guidance provide a foundation for evaluating scientific contributions in these fields.[1][2]

Abstract

This article presents an academic recognition profile for Ziqin Wang of Beijing Chaoyang Kaiwen Academy, China, in connection with the Innovative Research Award and the International Invention Awards. The stated subject areas are toxicology and pharmaceutical science, which encompass chemical safety, biological responses, therapeutic substances, and pharmaceutical development. The profile outlines relevant research themes and describes considerations for evaluating originality, methodological quality, scientific integrity, and practical relevance. Specific publications, research achievements, citation counts, and other bibliometric indicators have not been independently verified. Authoritative institutional records and scholarly databases should be consulted before attributing individual accomplishments or drawing conclusions about research impact or award eligibility.

Keywords

Ziqin Wang, Innovative Research Award, International Invention Awards, toxicology, pharmaceutical science, drug safety, pharmacological research, chemical risk assessment, pharmaceutical innovation, scientific research, biomedical development, research evaluation.

Introduction

Scientific innovation advances knowledge by introducing new methods, testing hypotheses, and addressing unresolved research questions. Toxicology and pharmaceutical science contribute to this process through investigations of chemical hazards, biological mechanisms, drug safety, and therapeutic development. Evaluating work in these areas requires attention to experimental design, reproducibility, ethical conduct, and the strength of supporting evidence. Internationally recognized scientific and pharmaceutical guidance provides useful context for understanding these requirements.[1][2]

Research Profile

The supplied information identifies Ziqin Wang with Beijing Chaoyang Kaiwen Academy in China and lists toxicology and pharmaceutical science as relevant subject areas. These fields combine concepts from chemistry, biology, pharmacology, and health sciences to examine the effects of substances and the development of therapeutic products. The available information does not independently establish a specific research appointment, degree, laboratory affiliation, or publication history. Additional details should be confirmed through institutional documentation, scholarly records, or the researcher’s verified public profile before inclusion in a formal academic biography.[3]

Research Contributions

Potential contributions within toxicology and pharmaceutical science include the assessment of chemical hazards, analysis of dose-response relationships, investigation of biological mechanisms, and development of improved methods for evaluating substance safety. Pharmaceutical research can also address formulation, drug delivery, analytical techniques, and the evaluation of therapeutic candidates. These examples describe the broader scientific disciplines and should not be interpreted as confirmed achievements by Ziqin Wang. Individual discoveries, inventions, experimental results, or original methods should be attributed only when supported by identifiable publications, patents, institutional records, or other reliable evidence.[1][2]

Publications

A verified publication record helps establish research activity, subject expertise, and scholarly contributions. Relevant materials may include peer-reviewed journal articles, conference papers, research reports, and publications describing original experimental findings. Each record should be checked for authorship, publication details, journal information, and a persistent identifier such as a digital object identifier (DOI), when available. No specific publication or DOI has been verified for this profile. Consequently, publication titles and numerical research indicators should be added only after checking appropriate scholarly databases and original publication records.[3]

Research Impact

Research impact can be examined through scientific quality, reproducibility, independent citation, practical application, and relevance to important research questions. In toxicology and pharmaceutical science, meaningful outcomes may include stronger safety assessment methods, improved understanding of biological effects, or evidence that supports further therapeutic development. Citation counts and h-index values can indicate aspects of scholarly visibility but cannot independently establish originality or practical benefit. An evidence-based assessment of Ziqin Wang’s research impact requires verified publications, documented research outputs, and independent evidence of how the work has contributed to scientific understanding or subsequent applications.[1]

Award Suitability

The Innovative Research Award provides a framework for recognizing work that may demonstrate originality, methodological rigor, scientific relevance, and responsible innovation. In toxicology and pharmaceutical science, a nomination may be supported by documented research findings, validated methods, relevant publications, patents, or evidence of practical application. The supplied profile information alone is insufficient to establish award eligibility or determine the strength of a nomination. A fair assessment should use the International Invention Awards’ applicable eligibility requirements and evaluation criteria, supported by reliable documentation and a transparent review process.[3]

Conclusion

This profile presents Ziqin Wang in the context of Beijing Chaoyang Kaiwen Academy, China, and the subject areas of toxicology and pharmaceutical science. It outlines the broader scientific context of the Innovative Research Award and the importance of originality, reproducibility, and evidence-based evaluation. A complete academic assessment requires verified scholarly outputs, documented research achievements, and confirmation of the relevant award criteria. The inclusion of numbered references links the discussion to sources on toxicological assessment, pharmaceutical guidance, and researcher identification, while maintaining a clear distinction between supplied profile information and independently established facts.

References

  1. ORCID. (n.d.). ORCID: Connecting Research and Researchers. ORCID.
    https://orcid.org/0009-0004-2036-3316
  2. Journal article. (2026. ) Cardiolipin-Specific Targeting of Melittin via Arg22 in Lipid Membranes: A Natural Toxin-Based Strategy for Treating Mitochondrial Dysfunction in Aging and Disease.
    https://doi.org/10.3390/toxins18100432
  3. International Invention Awards. (2026.). Official website.
    https://inventionawards.org/

Rupa Mazumder | Toxicology and Pharmaceutical Science | Best Researcher Award

Best Researcher Award

Rupa Mazumder
Noida Institute of Engineering And Technology

Rupa Mazumder
Affiliation Noida Institute of Engineering And Technology
Country India
Scopus ID 7005832705
Documents 211
Citations 1,412
h-index 18
Subject Area Toxicology and Pharmaceutical Science
Event International Invention Awards
ORCID 0000-0002-1888-548X

Rupa Mazumder is a researcher affiliated with the Noida Institute of Engineering And Technology, India, whose documented scholarly profile is associated with toxicology and pharmaceutical science. The supplied Scopus record reports 211 documents, 1,412 citations, and an h-index of 18, providing a bibliometric basis for considering the researcher within an academic recognition framework. [1]

Abstract

Rupa Mazumder is an India-based researcher affiliated with the Noida Institute of Engineering And Technology and associated with the subject area of Toxicology and Pharmaceutical Science. The supplied bibliometric profile records 211 scholarly documents, 1,412 citations, and an h-index of 18. These indicators provide measurable evidence of sustained research activity and scholarly visibility. Her profile is considered in relation to the Best Researcher Award under the International Invention Awards framework. Assessment of researcher recognition may consider publication productivity, citation influence, research continuity, subject expertise, and the broader relevance of scientific contributions. Bibliometric information should be interpreted alongside verified qualitative evidence and individual research outputs for balanced academic evaluation.

Keywords

Rupa Mazumder; Best Researcher Award; Toxicology; Pharmaceutical Science; Drug Research; Pharmacology; Research Impact; Scholarly Publications; Citation Analysis; h-index; Scientific Research; International Invention Awards.

Introduction

Researcher recognition in pharmaceutical and toxicological sciences commonly involves consideration of scholarly productivity, research quality, citation performance, and sustained engagement with scientific questions. Bibliometric indicators can provide a structured quantitative perspective, although they do not independently establish the originality or practical significance of individual studies. The available profile for Rupa Mazumder presents a substantial publication and citation record that can be examined as part of a broader academic assessment. [1] Standardized researcher identifiers such as Scopus Author ID and ORCID can also assist in distinguishing scholarly outputs and improving the reliability of attribution. [2]

Research Profile

The supplied profile identifies Rupa Mazumder with the Noida Institute of Engineering And Technology in India and places the research activity within Toxicology and Pharmaceutical Science. The reported Scopus Author ID is 7005832705, while the associated ORCID is 0000-0002-1888-548X. These persistent identifiers provide complementary mechanisms for connecting scholarly records with an individual researcher and can support verification across academic databases. [1] [2]

Research Contributions

Within toxicology and pharmaceutical science, research contributions may encompass the investigation of drug effects, safety, pharmacological mechanisms, toxicological responses, therapeutic development, and related biomedical questions. The available information does not provide a complete thematic inventory of Rupa Mazumder’s individual studies, so specific scientific claims should be based on verified publication records rather than inferred solely from bibliometric indicators. The documented publication volume nevertheless indicates sustained participation in scholarly research. [1]

Publications

The supplied Scopus information records 211 documents associated with the researcher profile. Publication counts are useful for describing research productivity but should be evaluated with attention to document type, authorship, journal quality, research field, chronology, and subject relevance. A complete publication assessment would require examination of the underlying indexed records and individual bibliographic metadata. The reported document count is therefore presented as a profile-level bibliometric indicator rather than as an independent measure of research quality. [1]

Research Impact

The supplied profile reports 1,412 citations and an h-index of 18. Citation indicators can help describe the visibility and scholarly uptake of published research, while the h-index combines productivity and citation dimensions into a single metric. Such measures vary across disciplines, career stages, database coverage, and publication practices and should therefore be interpreted within appropriate academic context. [1] Citation-based assessment is strongest when complemented by qualitative evidence concerning originality, methodological contribution, collaboration, and influence on subsequent research.

Award Suitability

The available bibliometric information provides a relevant quantitative foundation for consideration for the Best Researcher Award. The combination of 211 reported documents, 1,412 citations, and an h-index of 18 indicates an established scholarly record within the supplied profile. [1] Final award suitability should, however, be determined through verification of the researcher identity, publication record, research quality, originality, professional contributions, and alignment with the applicable award criteria. The profile therefore supports consideration without implying that bibliometric measures alone determine award outcome.

Conclusion

Rupa Mazumder’s supplied academic profile documents substantial scholarly activity in the field of Toxicology and Pharmaceutical Science, with 211 documents, 1,412 citations, and an h-index of 18. These indicators establish a useful quantitative basis for academic recognition while requiring contextual interpretation. [1] Verification through persistent researcher identifiers, indexed publications, and qualitative evidence can strengthen the assessment. On the information provided, the profile presents a credible basis for consideration under the Best Researcher Award category of the International Invention Awards.

References

  1. Elsevier. (n.d.). Scopus author details: Rupa Mazumder, Author ID 7005832705. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=7005832705
  2. ORCID. (n.d.). ORCID record: Rupa Mazumder, ORCID 0000-0002-1888-548X. ORCID.
    https://orcid.org/0000-0002-1888-548X
  3. Journal article. (2026).Preparations, Applications, Patents, and Marketed Formulations of Nanoemulsions – A Comprehensive Review.
    http://dx.doi.org/10.2174/0122117385325186240912110731
  4. Journal article. (2025). A Comprehensive Investigation on the Role of Bioactives on DYRK1A to Avert Alzheimer’s Disease.
    https://doi.org/10.18311/jnr/2025/49903
  5. International Invention Awards. (2026. ). Official award website.
    https://inventionawards.org/

Stephen Chelko | Toxicology and Pharmaceutical Science | Innovative Research Award

Innovative Research Award

Stephen Chelko
Florida State University College of Medicine

Stephen Chelko
Affiliation Florida State University College of Medicine
Country United States
Scopus ID 54973874200
Documents 47
Citations 1,649
h-index 18
Subject Area Toxicology and Pharmaceutical Science
Event International Invention Awards
ORCID 0000-0003-1675-5945

Stephen Chelko is a researcher affiliated with the Florida State University College of Medicine whose documented scholarly profile is associated with toxicology and pharmaceutical science. Available bibliometric information records 47 documents, 1,649 citations, and an h-index of 18, providing a quantitative basis for assessing research visibility and scholarly influence. [1]

Abstract

Stephen Chelko is a researcher associated with Florida State University College of Medicine and the fields of toxicology and pharmaceutical science. His indexed scholarly record comprises 47 documents, 1,649 citations, and an h-index of 18, according to the supplied Scopus profile information. These indicators provide a measurable basis for describing his research visibility and citation impact within scholarly databases. His profile may be considered in the context of recognition for innovative research, particularly where scientific investigation, translational relevance, and contribution to biomedical knowledge are central criteria. The Innovative Research Award provides a framework for highlighting documented scholarly achievement and research significance.

Keywords

Stephen Chelko; Innovative Research Award; toxicology; pharmaceutical science; biomedical research; Florida State University College of Medicine; research impact; scholarly publications; citation analysis; translational science.

Introduction

Academic recognition commonly considers the quality, relevance, originality, and influence of a researcher’s scholarly work. In this context, Stephen Chelko’s documented profile combines research activity in toxicology and pharmaceutical science with measurable bibliometric indicators. The available Scopus record identifies 47 documents, 1,649 citations, and an h-index of 18. [1]

Research Profile

Chelko’s stated subject area is Toxicology and Pharmaceutical Science, positioning his scholarly profile within disciplines concerned with biological effects, therapeutic development, pharmaceutical research, and related biomedical questions. His affiliation with Florida State University College of Medicine further places this work within an academic medical environment. [4]

Research Contributions

The available information supports describing Chelko’s contribution through his documented publication record and citation footprint rather than assigning unsupported claims about individual discoveries. Forty-seven indexed documents indicate sustained scholarly output, while the recorded citation count suggests that his published research has been referenced by subsequent academic literature. [1]

Publications

The supplied researcher profile reports 47 documents indexed in Scopus. Because complete publication titles, journals, publication years, and article-level DOI information were not supplied, this page does not attribute individual papers or DOI records without verification. The Scopus author profile provides the appropriate source for reviewing the complete indexed publication record. [1]

Research Impact

Research impact can be assessed through several complementary dimensions, including scholarly citations, publication continuity, disciplinary relevance, and potential contribution to scientific practice. Chelko’s reported 1,649 citations and h-index of 18 provide quantitative indicators of scholarly visibility, although bibliometric measures should be interpreted alongside qualitative assessment of research originality and significance. [1]

Award Suitability

The documented research profile is relevant to an Innovative Research Award because it demonstrates sustained scholarly activity in a biomedical subject area and a measurable citation record. Final award suitability should nevertheless depend on the official nomination criteria, verified publications, originality of contributions, supporting evidence, and independent evaluation by the responsible award committee. [5]

Conclusion

Stephen Chelko’s supplied academic profile presents a researcher working in toxicology and pharmaceutical science, affiliated with Florida State University College of Medicine. The reported record of 47 documents, 1,649 citations, and an h-index of 18 provides a measurable foundation for academic recognition. These indicators should be considered together with verified research quality and innovation.

References

  1. Elsevier. (n.d.). Scopus author details: Stephen Chelko, Author ID 54973874200. Scopus.
    https://www.scopus.com/pages/authors/54973874200
  2. ORCID. (n.d.). Stephen Chelko, ORCID iD 0000-0003-1675-5945. ORCID.
    https://orcid.org/0000-0003-1675-5945
  3. Google Scholar. (n.d.). Stephen Chelko — Google Scholar profile.
    https://scholar.google.com/citations?hl=en&user=5Hq6SM0AAAAJ
  4. Journal article. (2019.). Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy.
    https://doi.org/10.1161/CIRCULATIONAHA.119.040676
  5. International Invention Awards. (2026.). Official Award Information.
    https://inventionawards.org/

Ghazaleh Pouya | Pharmacology | Young Researcher Award

Ms. Ghazaleh Pouya | Pharmacology Science | Young Researcher Award

Ms. Ghazaleh Pouya | Sechenov University | Russia

Ms. Ghazaleh Pouya is an aspiring pharmaceutical scientist and multidisciplinary researcher, currently pursuing a Master’s degree in Biology at Sechenov University with a focus on Innovative Medicines. With a Doctor of Pharmacy (Pharm.D.) degree from the same university, she integrates her clinical pharmaceutical knowledge with advanced research in transdermal drug delivery and AI-powered biomedical solutions. As a lab assistant and assistant researcher, she actively contributes to academic publications, interdisciplinary projects, and data analytics in pharma-biotech. Her curiosity and dedication to translational medicine, wound healing systems, and personalized therapeutics reflect in her dynamic academic and research involvement, positioning her as a promising young innovator at the intersection of pharmacy, biology, and artificial intelligence.

Profile

ORCID

Education

Ms. Ghazaleh earned her Pharm.D. from Sechenov University, completing a thesis on in-vitro modeling of aero-dispersed film-forming systems. Currently, she is enrolled in a Master’s program in Biology, focusing on Innovative Medicines, at the same institution. In parallel, she undertakes applied IT training at School-21, a program dedicated to programming, app development, and clinical data analysis in medicine. Her multidisciplinary training bridges biological sciences, medical informatics, and pharmaceutical technologies. Ms. Ghazaleh’s strong academic background provides her with a unique perspective in drug delivery development and biomedical computation, preparing her for impactful contributions to pharmaceutical innovation and AI-assisted healthcare systems.

Experience

Ms. Ghazaleh Pouya is a laboratory assistant and student researcher at Sechenov University, actively involved in both experimental design and data analysis across pharmaceutical and biological domains, where she develops tools for clinical and pharmaceutical data evaluation. She collaborates with the Department of Pharmaceutical Technology, Department of Biology (Innovative Drugs), and the PHARMA-PREMIUM Scientific Research Center, contributing to a range of wound treatment, drug delivery, and AI-modeling projects. This diverse experience strengthens her competence in translational science, combining wet lab experimentation with computational modeling, ensuring real-world applicability of research findings.

Research Interests

Ms. Ghazaleh’s research focuses on transdermal drug delivery systems, pharmaceutical nanocarriers, and AI-integrated biomedical analytics. She is also exploring in vitro skin models, pharmacogenomics, and quality-by-design (QbD) strategies in formulation development. Her innovative mindset drives her to investigate how machine learning can optimize personalized drug delivery mechanisms, especially for wound treatment and skin permeability. She works on enhancing the bioavailability and targeted release of active substances using nano-based platforms, contributing to the next generation of smart drug delivery systems. Ghazaleh’s vision blends biological sciences, digital health, and pharmaceutical technology for patient-centered therapeutic innovations.

Award

Ms. Ghazaleh Pouya is a strong candidate for the “Young Researcher Award” under the International Invention Awards 2025. Her multidisciplinary background, three completed co-authored publications, ongoing research in pharmaceutical aerosols, and AI-driven drug delivery platforms reflect her impactful contributions at an early stage of her career. Her experience across pharmaceutical formulation, lab analytics, and computational modeling positions her among the emerging leaders in pharm-biotech research. Her self-driven participation in interdepartmental and interdisciplinary collaborations exemplifies the qualities of a future research innovator. This award would not only recognize her current achievements but also catalyze her continued excellence in translational research.

Publications

Transdermal Drug Delivery Systems: Methods for Enhancing Skin Permeability and Their Evaluation

Development of water vapor permeability determination methodology for spray film-forming systems

characterization and screening parameters of spray film-forming systems: a comprehensive study on dosage forms and quality indicators

Conclusion

Ms. Ghazaleh Pouya embodies the ideal profile of a rising biomedical innovator, integrating academic rigor, hands-on laboratory experience, and computational skills into a cohesive research journey. Her contributions to pharmaceutical sciences, particularly in film-forming drug systems and skin permeability, along with her novel integration of AI in drug delivery, showcase her potential to advance therapeutic design. With publications in reputable journals, active institutional collaborations, and an interdisciplinary mindset, she has already laid a strong foundation for a successful career in science and innovation. Recognition through the Young Researcher Award will further encourage her to expand her scientific impact and pursue future breakthroughs in personalized medicine and nanopharmaceuticals.

Dr. Dina Aboushady | Pharmaceutical Analysis | Best Researcher Award

Dr. Dina Aboushady | Pharmaceutical Analysis | Best Researcher Award

German University in Cairo, Egypt.

Dr. Dina Aboushady is a distinguished Postdoctoral Lecturer Assistant in the Faculty of Pharmacy and Biotechnology at the German University in Cairo (GUC), specializing in pharmaceutical chemistry. With a deep passion for drug design and bioanalysis, her research bridges innovative solutions in chiral recognition and pharmaceutical quality. She has significantly contributed to the development of quinazoline derivatives and enantiomeric resolution methods. Her career is marked by numerous awards, including prestigious scholarships and research fellowships. Dr. Aboushady also brings valuable teaching experience to her role at GUC and GIU (German International University).

Profile

Orcid

Education 🎓

Dr. Aboushady obtained her Bachelor's degree in Pharmacy and Biotechnology from the German University in Cairo (GUC) in 2014, graduating with highest honors. She continued her studies and earned a Master's of Science in Pharmaceutical Chemistry in 2016 with excellent grades. Her Doctor of Philosophy (Ph.D.) in Pharmaceutical Chemistry was awarded in 2021, focusing on Quality by Design for Bioanalysis and chiral recognition. Her commitment to research excellence was further recognized with scholarships such as the DAAD/BMBF/GUC funded fellowship and the full Ph.D. fellowship from GUC.

Experience 💼

Dr. Aboushady currently serves as a Postdoctoral Lecturer Assistant at GUC and a Part-time Lecturer at the German International University (GIU), teaching courses like Physical Chemistry, Analytical Chemistry, and Instrumental Analysis. Her teaching extends across several campuses in Cairo and Berlin. Additionally, she has contributed to various workshops such as Grant Writing and LC-MS Essential Operator workshops, emphasizing her active role in academic development and mentoring.

Research Interests 🔬

Pharmaceutical Chemistry Expertise 🔬
Dr. Dina Aboushady specializes in pharmaceutical chemistry, focusing on the design and synthesis of novel drug molecules. Her work includes developing innovative bioanalytical methods that advance the understanding and application of pharmaceutical compounds.

Enantio-Separation and Supercritical Fluid Chromatography (SFC) 🔍
A major part of Dr. Aboushady's research lies in enantio-separation, a process critical to the bioanalysis and quality control of pharmaceutical products. She utilizes supercritical fluid chromatography (SFC), a powerful technique to separate chiral compounds, enabling more precise drug quality assessment and development.

Chiral Recognition in Drug Design 💊
Dr. Aboushady's contributions to chiral recognition are pivotal in optimizing the effectiveness of pharmaceutical products. By understanding and improving how drugs interact with their chiral forms, she plays a crucial role in ensuring that drugs are both safe and effective.

Pharmaceutical Analysis and Drug Quality Control 🔬
Her research in pharmaceutical analysis focuses on improving drug quality control through advanced separation techniques. Dr. Aboushady’s work ensures that pharmaceutical products meet the required standards for efficacy and safety, contributing significantly to drug development and bioanalysis.

Awards 🏆

DAAD/BMBF/GUC Scholarship (2019-2020) for research stay in Germany.

Full Ph.D. Fellowship (2016-2021) at GUC.

Academic Excellence Scholarship (2009-2014) for Bachelor studies at GUC.

DAAD Scholarship for Drug Design Course (Summer 2013) in Germany.

Selected Publications 📚

Aboushady, D., Parr, M. K., Hanafi, R. S., Quality-by-Design Is a Tool for Quality Assurance in the Assessment of Enantioseparation of a Model Active Pharmaceutical Ingredient. Pharmaceuticals, 2020, 13(11), 364.

Aboushady, D., Rasheed, S. S., Herrmann, J., Novel 2,4-disubstituted quinazoline analogs as antibacterial agents with improved cytotoxicity profile. Bioorg Chem., 2021, 117, 105422.

Aboushady, D., Hanafi, R. S., Parr, M. K., Quality by design approach for enantioseparation of terbutaline and its sulfate conjugate metabolite for bioanalytical application using supercritical fluid chromatography. J Chromatogr A., 2022, 1676, 463285.

Aboushady, D., Samir, L., Masoud, A., Chemometric Approaches for Sustainable Pharmaceutical Analysis Using Liquid Chromatography. Chemistry, 2025, 7(1), 11.

 

 

Dr. Natascia Bruni | Chemistry | Best Researcher Award

Dr. Natascia Bruni | Chemistry | Best Researcher Award

Candioli Pharma srl, Italy.

Natascia Bruni is an experienced regulatory compliance and quality management professional with over two decades of experience in the pharmaceutical and feed supplements industries. Currently, she serves as the Compliance Unit Director, Qualified Person, and QPPV at Acel Pharma srl, where she plays a pivotal role in ensuring regulatory compliance, managing product registrations, and overseeing pharmacovigilance activities. Throughout her career, Natascia has worked across various sectors, including pharmaceutical companies (human and veterinary), focusing on quality assurance, regulatory affairs, and strategic business compliance. She is well-versed in navigating complex regulatory landscapes and has made substantial contributions to corporate governance, legal risk management, and quality audits.

Profile

Scopus

Orcid

Education 🎓

Natascia Bruni's educational background demonstrates her deep expertise in both scientific and management fields, which has greatly contributed to her successful career in regulatory affairs and quality management. She completed her degree in Chemistry (Nuclear) at the University of Turin from 1991 to 1996, earning the highest distinction with a final vote of 110/110 con lode. This solid foundation in chemistry equipped her with a thorough understanding of chemical processes and analytical methods, which would later be pivotal in her regulatory and quality assurance roles in the pharmaceutical industry.

In addition to her scientific education, Natascia pursued specialized training in Regulatory Affairs and Pharmacovigilance for Drugs between 2001 and 2002, sharpening her skills in the complex regulatory frameworks governing drug safety and compliance. This training became essential in her role as a Qualified Person and QPPV in various pharmaceutical companies, where she led efforts to ensure products met both safety and regulatory standards.

Furthermore, Natascia completed a Business Management Course from 2015 to 2018, which enhanced her leadership, strategic planning, and operational management abilities. This course helped her integrate business and regulatory perspectives, allowing her to lead teams and drive organizational success in compliance-related activities.

Natascia also deepened her technical expertise by attending the School in Technology Enhanced Chemical Synthesis from 1996 to 1999, where she learned advanced techniques in chemical synthesis that continue to inform her work in pharmaceutical and feed supplement regulatory processes. Her multi-disciplinary education has provided a strong foundation for her leadership role in compliance and regulatory affairs, combining scientific rigor with strategic management skills.

Experience 💼

Compliance Unit Director - Qualified Person - QPPV (2012–Present), Acel Pharma srl (Candioli Group), Beinasco (Torino)
Responsible for ensuring the regulatory compliance of raw materials and finished products, overseeing registration/approvals, and managing import/export activities. Works closely with various departments to ensure that all products sold comply with national and international regulations.

Quality Unit Manager & Qualified Person (2007–2012), Olon Spa (Fidia Group), Rodano (MI) and Settimo Torinese (To)
Led the harmonization of QA/QC and regulatory procedures across two sites, ensuring GMP and regulatory compliance for the company’s product portfolio. Managed communications with health authorities and conducted quality audits for suppliers.

Chemistry Department Responsible (1997–1999), Antibiotic Spa, Settimo Torinese (To)
Conducted independent research and developed experimental procedures within the research project scope.

Researcher (1996–1997), Antibiotic Spa, Settimo Torinese (To)
Developed analytical methods and processes in the field of pharmaceutical research.

Research Interests 🔬

Regulatory Compliance in Pharmaceutical Products 📜

Natascia is particularly interested in the regulatory compliance of both raw materials and finished products in the pharmaceutical industry. Her work emphasizes the critical importance of navigating complex regulatory frameworks and ensuring that all pharmaceutical products, especially those used in veterinary medicine, comply with the highest standards of food safety, quality control, and marketing.

Pharmacovigilance & Product Registration 💊

A key area of Natascia's research is in pharmacovigilance, particularly focusing on the monitoring and reporting of adverse effects for drugs, ensuring products maintain safety and compliance throughout their lifecycle. She explores the processes involved in product registration, striving to streamline the approvals and regulatory checks necessary for market entry, particularly in international markets.

Process Improvement Methodologies 🔧

Natascia is also keen on exploring process improvement methodologies within the regulatory compliance space. Her work in this area aims to enhance operational efficiency, reduce legal risks, and strengthen internal control structures. By continuously improving regulatory and operational processes, she contributes to creating a safer and more efficient regulatory environment for pharmaceutical companies, particularly in the feed supplement and veterinary drug sectors.

Awards 🏅

University Senate Award: Best Academic Graduate (1996)
Awarded for excellence in academic performance by the Presidency Council of the Italian Chamber.

OPTIME Award: Best Experimental Dissertation of the Year (1996)
Recognized by the Industrial Union for outstanding research work.

Publications 📚

"Molecular Characterization of the Gorgonzola Cheese Mycobiota and Selection of a Putative Probiotic Saccharomyces cerevisiae var. boulardii for Evaluation as a Veterinary Feed Additive" Published in Applied Microbiology, 2024, 4(2), pp. 650–664.

"Efficacy of a Dietary Supplement in Dogs with Osteoarthritis: A Randomized Placebo-Controlled, Double-Blind Clinical Trial"
Published in PLoS ONE, 2022, 17(2), e0263971.

"Chronic Kidney Disease and Dietary Supplementation: Effects on Inflammation and Oxidative Stress", Published in Veterinary Sciences, 2021, 8(11), 277.
"Chronic Intestinal Disorders in Humans and Pets: Current Management and the Potential of Nutraceutical Antioxidants as Alternatives", Published in Animals, 2022, 12(7), 812.